Bruker's Revenues Up 7 Percent in Q4 | GenomeWeb

This story has been updated to include comments from the company's Q4 earnings call.

NEW YORK (GenomeWeb News) – Bruker reported after the close of the market today that its revenues in the fourth quarter were up 7 percent year over year, rising to $552.1 million from $517.3 million in Q4 2012.

The increase was powered largely by the company's BioSpin group, which grew in the double-digits, benefiting from a surge in customer installations and acceptances during the quarter.

The results beat the average Wall Street estimate of $503.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.